Time will tell if we are doing the right thing for our patients. Cure, a premier healthcare innovation campus and hub for entrepreneurs in New York City, conducted the GLP1RA Survey in collaboration with the Deerfield Institute, a division of Deerfield Management Company, an affiliate of Cure
Because they target two different systems, many healthcare providers view them as complementary
McElroy said there are currently no clinical studies that have examined the effect of GLP-1s on symptoms of anorexia or atypical anorexia, largely because it is thought that obesity and eating disorders do not overlap in individual patients
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants